Krebs Biochemicals & Industries Reports Mixed Financial Performance in Q2 2024
Krebs Biochemicals & Industries, a microcap pharmaceutical company, has reported a flat performance in the second quarter of fiscal year 2024-2025. The company's annual operating cash flow has increased, but its PBT and net sales have decreased significantly. Investors should carefully evaluate these factors before making any investment decisions.
Krebs Biochemicals & Industries, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.
According to the financial report, Krebs Biochem has experienced a flat performance in the second quarter of the fiscal year 2024-2025. The company's score has dropped from 3 to -3 in the last three months.
However, there are some positive aspects to the company's financials. Krebs Biochem has recorded the highest annual operating cash flow of Rs 2.30 crore in the last three years. This indicates that the company has generated higher cash revenues from its business operations.
On the other hand, there are some concerning factors as well. The company's Profit Before Tax (PBT) less Other Income has fallen by 56.42% year on year, standing at Rs -5.85 crore in the September 2024 quarter. This shows a very negative trend in the near term. Additionally, the company's net sales have also decreased by 13.63% year on year, standing at Rs 12.86 crore in the same quarter. This indicates a negative trend in the near term for sales.
Overall, Krebs Biochemicals & Industries has reported a mixed financial performance for the quarter ending September 2024. Investors are advised to carefully consider these factors before making any investment decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
